CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞恶性肿瘤的 CAR-T 细胞治疗：细胞免疫治疗是否代表最佳治愈机会
英文原题：CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?
查看英文原题
CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已成功用于B细胞淋巴瘤和白血病。这一成功推动了CAR-T 疗法向T细胞恶性肿瘤拓展。T细胞淋巴瘤和T细胞急性淋巴细胞白血病（T-ALL）具有高度异质性，但在复发/难治阶段均预后不良，且缺乏新型靶向疗法。CAR-T 疗法为这些疾病带来有前景的治疗方案，但也面临多项挑战，最主要的是靶抗原通常同时存在于恶性和正常T细胞上，可能导致自相残杀和T细胞再生障碍。本文综述CAR-T 治疗T-ALL和T细胞淋巴瘤的现状，重点介绍T细胞恶性肿瘤近期临床研究的新数据，并探讨该领域未来研究可借鉴的经验。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy has proven successful for B-cell lymphomas and leukemias. This success has inspired the development of CAR-T for T-cell malignancies. T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL) are highly heterogenous diseases but are united by poor prognosis in the relapsed/refractory setting and the lack of any novel, targeted therapies.
CAR-T therapy is a promising solution for these diseases but carries a number of challenges, principally that target antigens are typically shared between malignant and normal T cells. This can cause issues with fratricide and T-cell aplasia. In this review we discuss the current state of CAR-T treatment for T-ALL and T-cell lymphomas, highlighting recent novel clinical data for T-cell malignancies and discuss lessons that can be learned for future research in this area.
论文信息
- 作者
- Maciocia N、Wade B、Maciocia P
- 单位
- Department of Haematology, University College London Cancer Institute, London, United Kingdom.United Kingdom
- 文献类型
- 综述
- 期刊
- Blood advances2025 Feb 25
- 原文标识
- PubMed 39715467 · DOI 10.1182/bloodadvances.2023012263
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →